DeForest McDuff

DeForest McDuff
DeForest McDuff
Director, Boston
(617) 917-5551
Antitrust/Competition Policy; Intellectual Property; Valuation and General Damages

DeForest McDuff, Ph.D. is an expert in applied business economics with extensive experience in consulting, finance, and economic research.  Dr. McDuff provides economic expertise in a variety of areas in litigation and business consulting, including economic damages, lost profits, reasonable royalty, intellectual property, commercial success, licensing, negotiation, antitrust, competition, financial analysis, and valuation.

Dr. McDuff earned his Ph.D. in Economics from Princeton University.  At Princeton, Dr. McDuff received a National Science Foundation Graduate Research Fellowship (awarded to 25 graduate students in economics nationwide each year) for his academic research in financial economics and applied microeconomics.  He has published research in several peer-reviewed academic journals and in widely reviewed industry publications.  Dr. McDuff graduated summa cum laude with undergraduate degrees in economics and mathematics from the University of Maryland.


Dr. McDuff’s business consulting experience ranges from start-ups to Fortune 500 companies to professional sports teams, and includes licensing, valuation, negotiations, pricing, business design, product launches, strategic decision-making, and a range of other topics.  His expert witness experience includes expert analysis and/or testimony on more than 50 expert reports and declarations, 35 depositions, and 10 trials in a diverse range of courts across the country.

  • IP damages.  Analysis of intellectual property damages (patents, trade secrets, trademarks) in a variety of industries, including pharmaceuticals, electronics, telecommunications, medical devices, biotechnology, and others.  Evaluation of lost profits, unjust enrichment, reasonable royalties, irreparable harm, and other economic considerations.
  • Antitrust harm and damages.  Analysis of antitrust harm and damages, including monopolization, price fixing, price discrimination, tying, and other economic considerations.
  • Class certification and damages.  Analysis of class certification and damages, including evaluation and implementation of commonality and typicality of damages to a proposed class and the estimation of those damages.
  • ANDA litigations.  Analysis in Abbreviated New Drug Application (ANDA) litigations pertaining to analysis of pharmaceutical markets and secondary considerations (e.g., commercial success, long-felt need).
  • Financial analysis.  Evaluation of asset prices, financial models, discounted cash flows, net present value, and a variety of other financial analyses.
  • Valuation.  Valuation of assets, including application of the income approach, market approach, and cost approach.  Application of valuation principles to intellectual property and other assets.
  • Strategic analysis.  Strategic analysis of business models, licensing, negotiation, pricing, and other economic analyses for businesses and organizations.